Abstract
The pleiotropic effects of statins, beyond their cholesterol-lowering properties, are much debated. In primary prevention, several observational cohort and case-control studies appear to show that statins reduce the incidence of venous thromboembolism by about 30%. In a single randomized placebo-controlled clinical trial (JUPITER), which included 17,000 patients, rosuvastatin 20mg/day reduced the risk of venous thromboembolism by 43%. However, these patients were at low risk of venous thromboembolism, and the frequency of the event was, in principle, low. In secondary prevention, several observational studies and post-hoc analyses of randomized clinical trials have suggested that statins may prevent recurrence of venous thromboembolism. However, none of these studies had enough scientific weight to form the basis of a recommendation to use statins for secondary prevention. The putative preventive effect of statins appears to be independent of plasma cholesterol concentration and could be a pharmacological property of the statin class, although a dose-effect relationship has not been demonstrated. The mechanism through which statins might prevent venous thrombosis is thought to involve their anti-inflammatory and antioxidant eff...Continue Reading
References
Aug 3, 2001·Archives of Internal Medicine·J G RayA Laupacis
Apr 11, 2003·The New England Journal of Medicine·Paolo PrandoniAntonio Girolami
Jul 25, 2003·The New England Journal of Medicine·Murali K DuggiralaKaren F Mauck
Apr 22, 2004·Journal of Thrombosis and Haemostasis : JTH·C J M DoggenB M Psaty
Apr 22, 2004·Journal of Thrombosis and Haemostasis : JTH·N K KabaUNKNOWN THROMBO Investigators
Aug 18, 2004·Fundamental & Clinical Pharmacology·Karine LacutDominique Mottier
Jul 27, 2005·Circulation·Sucharita Sen-BanerjeeMukesh K Jain
Jul 14, 2006·Journal of Thrombosis and Haemostasis : JTH·L M ReichM Cushman
Sep 12, 2006·Journal of Thrombosis and Haemostasis : JTH·P B van der HagenM Cushman
Dec 19, 2007·Circulation·Walter AgenoPieter W Kamphuisen
Nov 11, 2008·The New England Journal of Medicine·Paul M RidkerUNKNOWN JUPITER Study Group
Nov 28, 2008·Journal of Thrombosis and Haemostasis : JTH·A S RamcharanC J M Doggen
Mar 31, 2009·The New England Journal of Medicine·Robert J GlynnPaul M Ridker
Dec 25, 2009·European Heart Journal·Alessandro SquizzatoWalter Ageno
Aug 19, 2010·International Journal of Clinical Practice·V AgarwalC I Coleman
Jun 7, 2011·Thrombosis Research·Menaka PaiMark A Crowther
Nov 17, 2011·The New England Journal of Medicine·Stephen J NichollsSteven E Nissen
Oct 3, 2012·PLoS Medicine·Kazem RahimiJohn McMurray
Nov 6, 2012·The New England Journal of Medicine·Timothy A BrightonUNKNOWN ASPIRE Investigators
Feb 12, 2013·European Heart Journal·Sara Biere-RafiPieter W Kamphuisen
Apr 16, 2013·European Heart Journal·Kausik K Ray
Nov 2, 2013·Arteriosclerosis, Thrombosis, and Vascular Biology·Erin M HaldJohn-Bjarne Hansen
Nov 10, 2013·BMJ Open·Cu Dinh NguyenGunnar H Gislason
May 14, 2014·Journal of Thrombosis and Haemostasis : JTH·M SchmidtH T Sørensen
Feb 24, 2015·Thrombosis Journal·Philip S WellsAnthonie Wa Lensing
Apr 22, 2015·Thrombosis Research·Aneel A AshraniJohn A Heit
Citations
Mar 8, 2017·Current Opinion in Cardiology·Vanessa BianconiMatteo Pirro
Jul 21, 2017·Expert Review of Cardiovascular Therapy·Setor K KunutsorJari A Laukkanen
Jun 24, 2017·Anesthesia and Analgesia·Ronald J Gordon, Frederick W Lombard
Apr 4, 2017·European Heart Journal·Setor K KunutsorKamlesh Khunti
Jan 23, 2021·Seminars in Thrombosis and Hemostasis·Diletta OnoratoGiuseppe Lippi
Mar 12, 2021·Cardiovascular Research·Philip JosephSalim Yusuf
Mar 25, 2019·Thrombosis Research·Giuditta BenincasaClaudio Napoli
Jun 29, 2021·Thrombosis Journal·Mohammadreza BordbarWillem M Lijfering